Flavocure Biotech Inc.

Recent News

  • Flavocure Biotech, Inc. Announces a New Appointment to the Advisory Board

    Baltimore, Maryland--(Newsfile Corp. - June 7, 2021) - The Board and Management of Flavocure Biotech, Inc. ("Flavocure") a drug discovery and development company, announced today the appointment of Dr Thomas F. Woolf, PhD, an expert in pharmaceutical sciences to the company's Board of Advisors."Flavocure is a clinical stage ready company, and its first drug candidate targets pancreatic adenocarcinoma which is currently uncurable."Dr Woolf graduated from the University of Washington (Seattle, Washington) with a BS in Pharmacy; University of California...

    2021-06-07 2:16 PM EDT
  • Flavocure Biotech Announces Orphan Designation Granted by FDA for Caflanone (FBL-03G) in Pancreatic Cancer

    Baltimore, Maryland--(Newsfile Corp. - October 3, 2019) - Flavocure Biotech, Inc. ("Flavocure") a drug discovery and development company, announced today that the United States Food and Drug Administration (FDA) on September 25, 2019 granted Orphan drug status to its lead drug candidate, Caflanone (FBL-03G) for the treatment of Pancreatic Cancer. "We are very pleased to have received Orphan Drug designation from the FDA for Caflanone. This is a significant milestone that underscores Flavocure's successful innovations and drug development program," said...

    2019-10-03 7:38 PM EDT
  • Flavocure Receives "Green Light" from the United States Patent & Trademark Office and Announces Funding Opportunity

    Baltimore, Maryland--(Newsfile Corp. - September 18, 2019) - Flavocure Biotech Inc. ("Flavocure" or the "Company"), a cancer research and drug development company, is pleased to announce that the US Patent and Trademark Office has issued patent No. 10,398,674 for the "Therapeutic Agents Containing Flavonoid Cannabis Derivatives Targeting Kinases, Sirtuins, and Oncologic Agents for the Treatment of Cancers".This proprietary technology is applicable to the treatment of pancreatic related cancers and Flavocure has exclusive rights to the patented technology. Discovered...

    2019-09-18 9:00 AM EDT
  • Flavocure Pancreatic Drug Discovery Attracts Major Asian Equity Investor

    Baltimore, Maryland--(Newsfile Corp. - April 9, 2019) - Dr. Henry Lowe, the executive Chairman of Flavocure Biotech Inc, today announced that Denning Growth Fund ("DGF") has invested $1.5 million USD in Flavocure Biotech, Inc. a disruptive innovator in oncological drug discovery. DGF, which is controlled by one of Asia's richest tycoons, has added Flavocure to their life sciences portfolio. Dr. Henry Lowe stated, "The potential efficacy of Flavocure's drug has been validated in a large cohort study completed...

    2019-04-09 12:19 PM EDT
  • Flavocure Biotech, Inc. Announces Special Appointments to the Advisory Board and Regulatory Affairs

    Baltimore, Maryland--(Newsfile Corp. - February 25, 2019) - Dr. Henry Lowe Ph.D. announces - It is with pleasure that Flavocure Biotech, Inc. welcomes the creation of Advisory Board Chairman, reporting to the company's board of directors. In the creation of this new role, Dr. Jose Luis Calderon, M.D. has accepted the role as Chairman of the Advisory Board of Directors. Dr. Calderon, a graduate of Harvard Medical School, also serves as a member of the Division of General...

    2019-02-25 10:00 AM EST
  • Flavocure Announces Initiation of IND Enabling Studies for Drug to Treat Pancreatic and Glioblastoma Cancers

    Baltimore, Maryland--(Newsfile Corp. - January 16, 2019) -  Flavocure Biotech, Inc., announced today that it has initiated Investigational New Drug (IND) enabling studies for its cannabis derived drug, FBL-03G. The studies, which are estimated to cost over $1 million, have been independently sponsored by the company's Executive Vice Chairman, Clark Swanson. The commitment paves the way for Flavocure to attain IND status from the FDA. The effort is expected to be completed within 9 - 12 months,...

    2019-01-16 9:00 AM EST